Zobrazeno 1 - 10
of 45
pro vyhledávání: '"Carrie Brownstein"'
Autor:
David A. Sallman, Daniel J. DeAngelo, Naveen Pemmaraju, Shira Dinner, Saar Gill, Rebecca L. Olin, Eunice S. Wang, Marina Konopleva, Eileen Stark, Ana Korngold, Asifa Haider, Kate Backhouse, Carolyn Figliola, Daniel J. Lee, Mark G. Frattini, Carrie Brownstein, Gail J. Roboz
Publikováno v:
Blood. 140:2371-2373
Autor:
Stephen Jones, Joanne L. Blum, Silke Hoersch, Carrie Brownstein, Kristi McIntyre, Robert Brooks, Ragene Rivera, Scot Sedlacek, Deborah Lindquist, Svetislava Vukelja, Frankie Ann Holmes, Lea Krekow, John Pippen, Christopher Stokoe, Devchand Paul, Mark R. Lackner, Yuanyuan Xiao, Hartmut Koeppen, Joyce O'Shaughnessy
Figure S1: Forest plot of hazard ratios by subgroup in the ITT population (planned analysis) for (A) DFS and (B) OS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3060aaa198d6aa653ca0f4ffd008f780
https://doi.org/10.1158/1078-0432.22459091
https://doi.org/10.1158/1078-0432.22459091
Autor:
Stephen Jones, Joanne L. Blum, Silke Hoersch, Carrie Brownstein, Kristi McIntyre, Robert Brooks, Ragene Rivera, Scot Sedlacek, Deborah Lindquist, Svetislava Vukelja, Frankie Ann Holmes, Lea Krekow, John Pippen, Christopher Stokoe, Devchand Paul, Mark R. Lackner, Yuanyuan Xiao, Hartmut Koeppen, Joyce O'Shaughnessy
Figure S2: Distribution of central Ki-67 scores in (A) ER-positive/HER2-negative breast cancer (n=824) and (B) TNBC (n=454)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d27d672ffe281528bd28900935eb2264
https://doi.org/10.1158/1078-0432.22459088
https://doi.org/10.1158/1078-0432.22459088
Autor:
Stephen Jones, Joanne L. Blum, Silke Hoersch, Carrie Brownstein, Kristi McIntyre, Robert Brooks, Ragene Rivera, Scot Sedlacek, Deborah Lindquist, Svetislava Vukelja, Frankie Ann Holmes, Lea Krekow, John Pippen, Christopher Stokoe, Devchand Paul, Mark R. Lackner, Yuanyuan Xiao, Hartmut Koeppen, Joyce O'Shaughnessy
Figure S3: Forest plots for DFS comparing patients with central Ki-67 high versus low based on quartile cutoffs (exploratory analysis) in (A) ER-positive/HER2-negative breast cancer (n=824) and (B) TNBC (n=454)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93b8108ccf1454fb50313081af87067f
https://doi.org/10.1158/1078-0432.22459085
https://doi.org/10.1158/1078-0432.22459085
Autor:
Stephen Jones, Joanne L. Blum, Silke Hoersch, Carrie Brownstein, Kristi McIntyre, Robert Brooks, Ragene Rivera, Scot Sedlacek, Deborah Lindquist, Svetislava Vukelja, Frankie Ann Holmes, Lea Krekow, John Pippen, Christopher Stokoe, Devchand Paul, Mark R. Lackner, Yuanyuan Xiao, Hartmut Koeppen, Joyce O'Shaughnessy
Supplementary Tables S1-5. Table S1. Baseline demographic and disease characteristics of patients with central Ki-67 data available. Table S2. Concordance between central and local Ki-67 scores. Table S3. Percentage of patients with a DFS event or de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba8b1b4c0a02880f2887e7587f35652a
https://doi.org/10.1158/1078-0432.22459082.v1
https://doi.org/10.1158/1078-0432.22459082.v1
Autor:
Stephen Jones, Joanne L. Blum, Silke Hoersch, Carrie Brownstein, Kristi McIntyre, Robert Brooks, Ragene Rivera, Scot Sedlacek, Deborah Lindquist, Svetislava Vukelja, Frankie Ann Holmes, Lea Krekow, John Pippen, Christopher Stokoe, Devchand Paul, Mark R. Lackner, Yuanyuan Xiao, Hartmut Koeppen, Joyce O'Shaughnessy
Purpose: We conducted a randomized phase III study to determine whether patients with early breast cancer would benefit from the addition of capecitabine (X) to a standard regimen of doxorubicin (A) plus cyclophosphamide (C) followed by docetaxel (T)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a13e38c6829057d8cbd02caddd5506c
https://doi.org/10.1158/1078-0432.c.6524126.v1
https://doi.org/10.1158/1078-0432.c.6524126.v1
Autor:
Elizabeth Fox, Michael Berntgen, Alfonso Quintás-Cardama, Veronique Minard-Colin, Susan L. Weiner, André Baruchel, Laura Pearce, Karsten Nysom, Andrew D.J. Pearson, Danielle H. Taylor, Christian M. Zwaan, Nirali N. Shah, Yousif Matloub, Ivan D. Horak, Gregory H. Reaman, Gilles Vassal, Koen Norga, Claudia Rossig, Dominik Karres, Lori A. Ehrlich, Martina Schüßler-Lenz, Alberto S. Pappo, Joe McDonough, Martina A. Sersch, Nick Richardson, Donna Ludwinski, Abraham Bassan, Eric Bleickardt, Nicole Scobie, Stephen Gottschalk, Rob Pieters, Sarah K. Tasian, Courtney Johnson, Teresa de Rojas, Malcolm A. Smith, Franca Ligas, Lynley V. Marshall, Shannon L. Maude, Brenda J. Weigel, Nick Bird, Najat Bouchkouj, Behzad K. Masouleh, Sarah Beaussant Cohen, Delphine Heenen, Rosanna Ricafort, G. Lesa, Linda Hanssens, Peter F. Bross, Carrie Brownstein, Crystal L. Mackall, Martin Pule, Douglas S. Hawkins, Jaroslav Sterba, Maksim Mamonkin
Publikováno v:
European Journal of Cancer. 160:112-133
The seventh multi-stakeholder Paediatric Strategy Forum focused on chimeric antigen receptor (CAR) T-cells for children and adolescents with cancer. The development of CAR T-cells for patients with haematological malignancies, especially B-cell precu
Autor:
Andrew Dj, Pearson, Claudia, Rossig, Crystal, Mackall, Nirali N, Shah, Andre, Baruchel, Gregory, Reaman, Rosanna, Ricafort, Delphine, Heenen, Abraham, Bassan, Michael, Berntgen, Nick, Bird, Eric, Bleickardt, Najat, Bouchkouj, Peter, Bross, Carrie, Brownstein, Sarah Beaussant, Cohen, Teresa, de Rojas, Lori, Ehrlich, Elizabeth, Fox, Stephen, Gottschalk, Linda, Hanssens, Douglas S, Hawkins, Ivan D, Horak, Danielle H, Taylor, Courtney, Johnson, Dominik, Karres, Franca, Ligas, Donna, Ludwinski, Maksim, Mamonkin, Lynley, Marshall, Behzad K, Masouleh, Yousif, Matloub, Shannon, Maude, Joe, McDonough, Veronique, Minard-Colin, Koen, Norga, Karsten, Nysom, Alberto, Pappo, Laura, Pearce, Rob, Pieters, Martin, Pule, Alfonso, Quintás-Cardama, Nick, Richardson, Martina, Schüßler-Lenz, Nicole, Scobie, Martina A, Sersch, Malcolm A, Smith, Jaroslav, Sterba, Sarah K, Tasian, Brenda, Weigel, Susan L, Weiner, Christian Michel, Zwaan, Giovanni, Lesa, Gilles, Vassal
Publikováno v:
European journal of cancer
European journal of cancer, 160:112-133
European journal of cancer, 160:112-133
The seventh multi-stakeholder Paediatric Strategy Forum focused on chimeric antigen receptor (CAR) T-cells for children and adolescents with cancer. The development of CAR T-cells for patients with haematological malignancies, especially B-cell precu
Autor:
Sarah A. Holstein, Nizar Bahlis, P. Leif Bergsagel, Manisha Bhutani, Niccolo Bolli, Carrie Brownstein, Pierre Demolis, David Foureau, Francesca Gay, Irene M. Ghobrial, Nicole Gormley, Jens Hillengass, Martin Kaiser, Marcela V. Maus, J. Joseph Melenhorst, Maximilian Merz, Michael O. Dwyer, Bruno Paiva, Marcelo C. Pasquini, Nina Shah, Sandy W. Wong, Saad Z. Usmani, Philip L. McCarthy
Publikováno v:
Transplant Cell Ther
Transplantation and cellular therapy, vol 27, iss 10
Transplantation and cellular therapy, vol 27, iss 10
The fifth annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma was conducted as one of the American Society of Hematology Annual Meeting Sc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d79ec414d86fe8eb620dacd754421351
http://hdl.handle.net/2318/1791012
http://hdl.handle.net/2318/1791012
Autor:
Moshe Talpaz, Carrie Brownstein, Tymara Berry, Juan Shen, Eric Jourdan, Srdan Verstovsek, Nicolaas Schaap, Claire N. Harrison, Harry C. Schouten, Richard T. Silver, Shelonitda Rose, Ruben A. Mesa, Jean-Jacques Kiladjian, Alessandro M. Vannucchi, Sonja Zweegman, Francesco Passamonti
Publikováno v:
American Journal of Hematology, 95(6), 594-603. Wiley
American Journal of Hematology, 95, 594-603
American Journal of Hematology
Harrison, C N, Schaap, N, Vannucchi, A M, Kiladjian, J J, Jourdan, E, Silver, R T, Schouten, H C, Passamonti, F, Zweegman, S, Talpaz, M, Verstovsek, S, Rose, S, Shen, J, Berry, T, Brownstein, C & Mesa, R A 2020, ' Fedratinib in patients with myelofibrosis previously treated with ruxolitinib : An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure ', American Journal of Hematology, vol. 95, no. 6, pp. 594-603 . https://doi.org/10.1002/ajh.25777
American Journal of Hematology, 95, 6, pp. 594-603
American Journal of Hematology, 95(6), 594-603. Wiley-Liss Inc.
American Journal of Hematology, 95, 594-603
American Journal of Hematology
Harrison, C N, Schaap, N, Vannucchi, A M, Kiladjian, J J, Jourdan, E, Silver, R T, Schouten, H C, Passamonti, F, Zweegman, S, Talpaz, M, Verstovsek, S, Rose, S, Shen, J, Berry, T, Brownstein, C & Mesa, R A 2020, ' Fedratinib in patients with myelofibrosis previously treated with ruxolitinib : An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure ', American Journal of Hematology, vol. 95, no. 6, pp. 594-603 . https://doi.org/10.1002/ajh.25777
American Journal of Hematology, 95, 6, pp. 594-603
American Journal of Hematology, 95(6), 594-603. Wiley-Liss Inc.
Contains fulltext : 220650.pdf (Publisher’s version ) (Open Access) Fedratinib is an oral, selective Janus kinase 2 (JAK2) inhibitor. The phase II JAKARTA2 study assessed fedratinib in patients with intermediate- or high-risk myelofibrosis (MF) who
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58c760202f3ed0846e8d53c2418d1bb1
https://cris.maastrichtuniversity.nl/en/publications/ab793601-9c16-42c0-9fb3-e453a23756e7
https://cris.maastrichtuniversity.nl/en/publications/ab793601-9c16-42c0-9fb3-e453a23756e7